The patient has been diagnosed with ... and has been referred for the OICR Genomics ... assay through the ... study. This test uncovered ... oncogenic mutations most commonly altered genes in ... cancer (DOI:[10.1038/nature](https://www.nature.com/)). While there is no FDA-approved therapeutic option for this mutation in ..., ... are FDA-approved for treatment with .... Copy Number Analysis returned ... .  There are currently no therapies associated with these alterations. The tumour had an estimated ploidy of ... and the mutational burden was ... coding mutations per Mb, which is ... (mean ... coding mutations/Mb, DOI:[DOI:10.1038/nature](https://www.nature.com/)). &alpha;&beta;&gamma;&delta;